These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24810474)

  • 1. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.
    Cai J; Yang P; Zhang C; Zhang W; Liu Y; Bao Z; Liu X; Du W; Wang H; Jiang T; Jiang C
    Oncotarget; 2014 May; 5(9):2551-61. PubMed ID: 24810474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
    Liu XY; Gerges N; Korshunov A; Sabha N; Khuong-Quang DA; Fontebasso AM; Fleming A; Hadjadj D; Schwartzentruber J; Majewski J; Dong Z; Siegel P; Albrecht S; Croul S; Jones DT; Kool M; Tonjes M; Reifenberger G; Faury D; Zadeh G; Pfister S; Jabado N
    Acta Neuropathol; 2012 Nov; 124(5):615-25. PubMed ID: 22886134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
    Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
    Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
    Shao LW; Pan Y; Qi XL; Li YX; Ma XL; Yi WN; Zhang J; Zhong YF; Chang Q
    Histol Histopathol; 2016 Jan; 31(1):103-14. PubMed ID: 26395639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.
    Kannan K; Inagaki A; Silber J; Gorovets D; Zhang J; Kastenhuber ER; Heguy A; Petrini JH; Chan TA; Huse JT
    Oncotarget; 2012 Oct; 3(10):1194-203. PubMed ID: 23104868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
    Jain S; Gupta P; Shankar KB; Singh R; Siraj F
    J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
    Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
    Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations.
    Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T
    Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.
    Cryan JB; Haidar S; Ramkissoon LA; Bi WL; Knoff DS; Schultz N; Abedalthagafi M; Brown L; Wen PY; Reardon DA; Dunn IF; Folkerth RD; Santagata S; Lindeman NI; Ligon AH; Beroukhim R; Hornick JL; Alexander BM; Ligon KL; Ramkissoon SH
    Oncotarget; 2014 Sep; 5(18):8083-92. PubMed ID: 25257301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
    Jiao Y; Killela PJ; Reitman ZJ; Rasheed AB; Heaphy CM; de Wilde RF; Rodriguez FJ; Rosemberg S; Oba-Shinjo SM; Nagahashi Marie SK; Bettegowda C; Agrawal N; Lipp E; Pirozzi C; Lopez G; He Y; Friedman H; Friedman AH; Riggins GJ; Holdhoff M; Burger P; McLendon R; Bigner DD; Vogelstein B; Meeker AK; Kinzler KW; Papadopoulos N; Diaz LA; Yan H
    Oncotarget; 2012 Jul; 3(7):709-22. PubMed ID: 22869205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
    Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
    J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres.
    Borodovsky A; Meeker AK; Kirkness EF; Zhao Q; Eberhart CG; Gallia GL; Riggins GJ
    J Neurooncol; 2015 Feb; 121(3):479-87. PubMed ID: 25471051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors.
    Cai J; Chen J; Zhang W; Yang P; Zhang C; Li M; Yao K; Wang H; Li Q; Jiang C; Jiang T
    Oncotarget; 2015 Jul; 6(20):18105-15. PubMed ID: 25971279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas.
    Ikemura M; Shibahara J; Mukasa A; Takayanagi S; Aihara K; Saito N; Aburatani H; Fukayama M
    Histopathology; 2016 Aug; 69(2):260-7. PubMed ID: 26741321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
    Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z
    Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.
    Grandin N; Pereira B; Cohen C; Billard P; Dehais C; Carpentier C; Idbaih A; Bielle F; Ducray F; Figarella-Branger D; Delattre JY; Sanson M; Lomonte P; Poncet D; Verrelle P; Charbonneau M;
    Acta Neuropathol Commun; 2019 Nov; 7(1):175. PubMed ID: 31706351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
    Ahmadi R; Stockhammer F; Becker N; Hohlen K; Misch M; Christians A; Dictus C; Herold-Mende C; Capper D; Unterberg A; von Deimling A; Wick W; Hartmann C
    J Neurooncol; 2012 Aug; 109(1):15-22. PubMed ID: 22528790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.